CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2009	$ 0	$ 50,003	$ 46,454,482	$ (25,000)	$ (40,407,607)	$ 6,071,878
Balance (in shares) at Dec. 31, 2009	0	50,002,887
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee share-based compensation expense	0	0	996,307	0	0	996,307
Other share-based compensation expense	0	0	174,354	0	0	174,354
Beneficial conversion feature recognized on convertible debt	0	0	287,448	0	0	287,448
Sale of common stock and warrants	0	3,713	3,118,307	0	0	3,122,020
Sale of common stock and warrants (in shares)		3,713,433
Exercise of stock options	0	211	154,915	0	0	155,126
Exercise of stock options (in shares)		210,250
Exercise of warrants	0	3,219	3,216,130	0	0	3,219,349
Exercise of warrants (in shares)		3,219,348
Shares issued in conjunction with conversion of convertible debt	0	7,236	3,486,563	0	0	3,493,799
Shares issued in conjunction with conversion of convertible debt (in shares)		7,235,992
Net loss for the period	0	0	0	0	(11,419,753)	(11,419,753)
Balance at Dec. 31, 2010	0	64,382	57,888,506	(25,000)	(51,827,360)	6,100,528
Balance (in shares) at Dec. 31, 2010	0	64,381,910
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee share-based compensation expense	0	0	1,307,869	0	0	1,307,869
Other share-based compensation expense	0	0	351,214	0	0	351,214
Beneficial conversion feature recognized on convertible debt	0	0	2,715,552	0	0	2,715,552
Warrants issued in conjunction with convertible promissory notes	0	0	14,885	0	0	14,885
Discount on benefical conversion feature recognized on line of credit with related party	0	0	80,000	0	0	80,000
Sale of common stock and warrants	0	3,779	3,726,808	0	0	3,730,587
Sale of common stock and warrants (in shares)		3,778,321
Exercise of stock options	0	490	295,263	0	0	295,753
Exercise of stock options (in shares)		490,000
Shares issued in conjunction with conversion of convertible debt	0	406	406,257	0	0	406,663
Shares issued in conjunction with conversion of convertible debt (in shares)		406,664
Shares issued in conjunction with acquisition of Surgical Biologics, LLC	0	5,250	7,082,250	0	0	7,087,500
Shares issued in conjunction with acquisition of Surgical Biologics, LLC (in shares)		5,250,000
Net loss for the period	0	0	0	0	(10,193,986)	(10,193,986)
Balance at Dec. 31, 2011	$ 0	$ 74,307	$ 73,868,604	$ (25,000)	$ (62,021,346)	$ 11,896,565
Balance (in shares) at Dec. 31, 2011	0	74,306,895